The American pharmaceutical group Pfizer estimates that sales of the anti-Covid vaccine, developed in partnership with the German company BioNTech, will reach around $ 15 billion over the whole of 2021, a colossal sum that could increase if the laboratory signs additional contracts. .
• Read also: The latest developments of the coronavirus
This vaccine would thus be one of the biggest “blockbusters” in the history of pharmacy.
Pfizer, which released its quarterly results on Tuesday, expects to generate a pre-tax margin on this product of around 25% to 30%.
It has already sold in the fourth quarter for 154 million dollars of the vaccine, authorized in several countries at the end of 2020.
Pfizer, which had provided an initial estimate of its adjusted earnings per share in early January, noted it following more refined calculations on the potential income from the vaccine: it now expects adjusted earnings per share of between 3 , 10 and 3.20 dollars against 3.00 to 3.10 dollars previously.
This profit is the indicator monitored by financial circles to measure the profitability of a company, because it does not take into account elements external to performance such as taxes and certain costs.
Total revenue in 2021 is expected to reach $ 59.4 billion to $ 61.4 billion, which would be an increase of between 42% and 47%.
These forecasts, Pfizer stresses, are based on the assumption of a “continued recovery in macroeconomic activity and health throughout 2021 as populations are vaccinated against COVID-19”.
In the fourth quarter of 2020, Pfizer’s revenue increased 12% to $ 11.7 billion. It was driven by the increase in sales of treatments against different types of cancer (+ 23%) and of all the group’s vaccines (+ 17%).
The laboratory, which recorded a net loss of $ 333 million in Q4 2019, returned to the green with a net profit of $ 534 million.
Over the year as a whole, the group’s sales, which in November separated from its non-patented medicines subsidiary Upjohn to merge it with Mylan and form Viatris, rose 2% to 41.91 billions of dollars.
Its net profit fell 41% to $ 9.6 billion.